A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Abstract Background HDIL-2 is approved for advanced melanoma based on its durable antitumor activity. MAGE-A3 cancer immunotherapeutic (MAGE-A3 CI) is a recombinant MAGE-A3 protein combined with an immunostimulant adjuvant system and has shown antitumor activity in melanoma. We assessed the safety a...

Full description

Bibliographic Details
Main Authors: Jennifer L. McQuade, Jade Homsi, Carlos A. Torres-Cabala, Roland Bassett, Rashmi Murthy Popuri, Marihella L. James, Luis M. Vence, Wen-Jen Hwu
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cancer
Subjects:
Melanoma
Immunotherapy
HDIL-2
MAGE-A3 CI
Online Access:http://link.springer.com/article/10.1186/s12885-018-5193-9

Internet

http://link.springer.com/article/10.1186/s12885-018-5193-9

Similar Items